Olaparib maintenance (BRCA-mut PDAC post-platinum, POLO)
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.
| Components | DRUG-OLAPARIB |
|---|
| ID | REG-OLAPARIB-MAINT-PDAC |
|---|---|
| Type | Regimen |
| Status | reviewed 2026-04-26 | pending_clinical_signoff |
| Diseases | None declared |
| Sources | SRC-ESMO-PANCREATIC-2024 SRC-NCCN-PANCREATIC-2025 |
Notes
POLO trial: olaparib maintenance in germline BRCA-mut mPDAC after ≥16 weeks platinum-based induction without progression — mPFS 7.4 vs 3.8 mo placebo (OS endpoint NS but PFS practice-changing). Long-term MDS/AML risk warrants pre-treatment counseling.
Used By
Indication
IND-PDAC-MAINTENANCE-OLAPARIB-BRCA- IND-PDAC-MAINTENANCE-OLAPARIB-BRCA